Efficacy of ICU-VTE Scale in ICU Patients

Completed

• Conditions: Venous Thromboembolism

• Registration Number: NCT05487066
• Lead Sponsor: Lijuan Zhang

Brief Summary

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among critically ill patients. No uniform standard model of VTE risk for critically ill patients was formatted by now. In 2020, Viarasilpa et al. developed the ICU⁃VTE rating table, mainly for ICU patients. However, it lacks validation. We examined and compared how well the ICU-VTE score predict and stratify VTE risk in comprehensive ICU patients.

Detailed Description

Venous thromboembolism (VTE) is a group of thromboembolic diseases including deep vein thrombosis (DVT) and pulmonary thromboembolism (PE), which is a systemic disease caused by a combination of risk factors. The risk of venous thromboembolism can be greatly reduced by the preventive treatment of it in hospitalized patients according to their risk level. The common risk assessment tools for inpatient VTE include the Padua score for medical patients and the Caprini score for surgical patients, but there is no clinical basis for implementing risk assessment for critically ill patients. The question of how to perform VTE risk assessment in ICU patients to prevent and treat the occurrence of VTE is worth exploring.

This study was designed according to a prospective study method. Data and information were collected from the time the patients were admitted to the ICU to the time the patients were discharged from the ICU.There are three purposes for this study. First, to observe the predictive effect and evaluate the value of the ICU-VTE scoring scale in comprehensive ICU patients; Second, to compare the advantages and disadvantages of the ICU-VTE scoring tool with the Padua score (internal medicine) and Caprini score tool (surgery); To analyze the risk factors for VTE in comprehensive ICU patients and to optimize the VTE risk prediction model; Third, to look into the prevention and treatment of VTE in critically ill ICU patients.

Study Timeline

• Study Start: 2022-05-01
• Study First Submitted: 2022-07-26
• Study First Submitted QC: 2022-08-02
• Study First Posted: 2022-08-04
• Primary Completion: 2023-12-10
• Study Completion: 2023-12-10
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 269

Inclusion Criteria

• patients age greater than or equal to 18 years;
• Patients or their family members agreed to the study and signed informed consent.

Exclusion Criteria

• Patients admitted to ICU with VTE diagnosis or diagnosed with VTE within 24 hours of admission to ICU;
• Use the therapeutic dose of anticoagulation before admission to ICU or within 24 hours in ICU;
• Expected ICU stay of less than 48 hours;
• Patients cannot obtain imaging data to confirm the presence of VTE during ICU admission

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
incidence of VTE	28-day	inhospital venous thromboembolism occurrence

Secondary Outcome Measures

Name	Time	Method
all-cause mortality	28-day	Death from all causes during hospitalization

Trial Locations

Locations (1)

The Central Hospital of Wuhan; 🇨🇳 Wuhan, Hubei, China